What is HC Wainwright’s Forecast for ZVRA FY2024 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of Zevra Therapeutics in a research report issued to clients and investors on Wednesday, November 20th. HC Wainwright analyst O. Livnat now forecasts that the company will earn ($1.92) per share for the year, down from their previous forecast of ($1.74). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $0.77 EPS and FY2027 earnings at $1.86 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. During the same period last year, the company earned ($0.40) EPS.

Several other research firms have also recently weighed in on ZVRA. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Guggenheim began coverage on shares of Zevra Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $20.00 price target for the company. Maxim Group upped their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Finally, Roth Mkm upped their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock opened at $9.59 on Friday. The firm has a 50 day simple moving average of $8.16 and a 200-day simple moving average of $6.60. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.64. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The stock has a market cap of $511.65 million, a price-to-earnings ratio of -4.63 and a beta of 1.93.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ZVRA. International Assets Investment Management LLC lifted its holdings in Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after buying an additional 5,940 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Zevra Therapeutics in the 1st quarter valued at $64,000. The Manufacturers Life Insurance Company raised its holdings in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares in the last quarter. Hunter Associates Investment Management LLC acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at $92,000. Finally, XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at $94,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.